AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03440593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caloric delivery will target results of IC measurement.
Description: The prescribed calories to be delivered will be set to target the measurement obtained from performing indirect calorimetry (IC). IC measures the gas exchange of oxygen consumption and carbon dioxide production to determine the true metabolic needs for cellular respiration. The expenditure of calories will be measured utilizing the gas module incorporated within the General Electric Carescape R860 ventilators.
Study NCT03223571 — intervention group
Intervention type: OTHER
Intervention: Motor rehabilitation training
Description: Post-stroke participants receive 6 week of rehabilitation training of the paretic upper-limb.
Study NCT01868360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subconjunctival aflibercept
Description: subconjunctival aflibercept injection
Study NCT03005184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan 200 mg bid
Description: oral medication
Study NCT01868360 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Standard of care only
Description: Patients will receive standard of care (steroids and cyclosporine) treatment only.
Study NCT00912119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epsilon-Aminocaproic Acid
Description: Group A (low dose) will receive a loading dose of EACA of 25 mg/kg over ten minutes followed by a continuous EACA infusion at 10 mg/kg/hr, which will be continued until the end of surgery
Study NCT03550560 — intervention group
Intervention type: PROCEDURE
Intervention: EUS-Guided drainage
Description: Drainage of refractory malignant ascites by endoscopic ultrasound-guided (EUS-Guided) implantation of plastic prostheses.
Study NCT01404663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD133 stem cell injection
Description: Bone marrow derived CD133 stem cell witch are transplanted by intrathecal injection
Study NCT03327233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connecare self managment system
Description: The CONNECARE SMS will rely on a hybrid solution that, besides being autonomous (the patient may use the SMS to monitor and access to her/his data and information), has also a collaborative component (through the interaction with the SACM) to allow participation by clinicians and to provide feedback to them. In so doing, the patient may control her/his activity, receiving recommendations to improve the treatment and to be encouraged in following it.
Study NCT02597062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Study NCT02597062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02924883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg IV infusion
Study NCT02924883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: Trastuzumab emtansine 3.6 mg/kg IV infusion
Study NCT02924883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab emtansine
Description: Trastuzumab emtansine 3.6 mg/kg IV infusion
Study NCT03005184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: intravenous medication
Study NCT03005184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intravenous medication
Study NCT02924883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to atezolizumab
Study NCT02924883 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matched to atezolizumab
Study NCT00445003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injection of 0.5 mg ranibizumab at baseline and 4 weeks
Study NCT00445003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Intravitreal injection of 4 mg triamcinolone acetonide at baseline and sham injection at 4 weeks
Study NCT00445003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sham injection
Description: Sham injection at baseline and 4 weeks
Study NCT00445003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal/grid laser
Description: Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
Study NCT00445003 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Focal/grid laser
Description: Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
Study NCT00832832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eyelid closure
Description: Eyelid will be closed after eye drop instillation
Study NCT00832832 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention will be assigned
Description: No intervention will be assigned to this arm
Study NCT04962256 — intervention group
Intervention type: PROCEDURE
Intervention: Enhanced recovery after surgery
Description: ERAS management includes 3 parts: (1) Preoperative analgesia and airway evaluation. (2) The protection and reconstruction of the musculo-ligamentous complex during the surgery, the safe intubation, and the local infiltration anesthesia during surgery. (3) Collar free, multimodal analgesia, airway management, and early recovery after surgery.
Study NCT04645121 — intervention group
Intervention type: DEVICE
Intervention: Carbon Monoxide-based Rebreathing
Description: 6 minutes Carbon Monoxide-based Rebreathing that estimate blood volume, plasma volume and erythrocyte volume.
Study NCT01987011 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG1109
Study NCT01987011 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03568565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ePREP Program
Description: see arm descriptions
Study NCT03568565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OurRelationship Program
Description: see arm descriptions
Study NCT04321850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate 50 Mg Tab
Description: The tablets were manufactured specifically for this study.
Study NCT04321850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: The tablets were manufactured specifically for this study.
Study NCT01837654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plantarflexion 2nd wave
Description: At the beginning of the 2nd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
Study NCT01837654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plantarflexion - 3rd wave
Description: At the beginning of the 3rd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
Study NCT02845739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kidney transplanted patients
Study NCT01141426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Short-term Dynamic Psychotherapy
Description: The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation of depression and perpetuation of depression. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and mood. The research protocol calls for the treatment to be delivered according to a 20-session time-limited format. The first session is an extended 2-3 hour appointment (21), then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Termination in fewer sessions is based upon agreement between therapist and patient.
Study NCT01141426 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Secondary Care Treatment as Usual
Description: At the four secondary health care sites, treatment as usual will consist of a multidisciplinary team approach including pharmacotherapy and clinical management, supportive or structured activities focused around symptom management and in some cases, individual or group psychotherapy. Pharmacotherapy treatment strategies will be individualized regimes informed by evidence-based recommendations. TAU will not be regulated in order to get a naturalistic assessment of standard secondary care treatment delivery with the exception that trial participants not be offered a psychodynamic / psychoanalytic based psychotherapy treatment during the course of the trial. Therapeutic interventions are likely to be heterogeneous therefore the trial coordinator will document in detail the dose and approaches delivered to each participant in order to account for this heterogeneity.
Study NCT02587871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT02587871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02587871 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo microtransplant
Study NCT02587871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Allogeneic Lymphocytes
Description: Undergo microtransplant
Study NCT02587871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF mobilized peripheral blood cells
Description: microtransplantation
Study NCT04584268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness
Description: in person and smart phone application mindfulness practice
Study NCT04584268 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard medical education
Description: standard medical education / control
Study NCT02039908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Children will receive a double-blind assessment to determine their optimal starting dose of Concerta. Doses will be adjusted over the course of the school year and inceased if tolerance to the medication is detected.
Study NCT03455348 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: catheter insertion
Description: catheter insertion one to less than 4 four centimeters to the wrist joint (Group A) and the other, to more than four centimeters to the wrist joint. (Group B)
Study NCT04645121 — intervention group
Intervention type: DEVICE
Intervention: Bioimpedance
Description: Measures total volume, intra and extracellular volume.
Study NCT06774716 — intervention group
Intervention type: BEHAVIORAL
Intervention: Internet-based cognitive behavioural treatment and relapse prevention
Description: A self help program consisting of 12 modules and access to therapist guidance through messages. Including three video session.
Study NCT06774716 — intervention group
Intervention type: BEHAVIORAL
Intervention: Face-to-face cognitive behavioural treatment or short-term psycodynamic therapy with relapse prevention
Description: Face-to-face therapy with a licenced psychologist or licenced psychotherapist, including 10-15 sessions.
Study NCT06772883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sexual education and counseling
Description: The women included in the Working Group were contacted by phone and invited to the hospital. Sexual education and counseling were provided in accordance with the PLISSIT model. A total of 5 interviews were conducted with the women, the first face-to-face interview and the subsequent ones by telephone. FSFI assessments in the study FSFI assessments were performed 5 times (initial, 1st, 3rd, 6th months and 1 year later). According to the PLISSIT model, their sexuality and any problems since the previous assessment were discussed and a short counseling was given if necessary.
Study NCT06772883 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: routine clinical care
Study NCT03451851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive a weight-based dose of guselkumab subcutaneously.
Study NCT03451851 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Guselkumab
Description: Participants will receive a weight-based dose of guselkumab subcutaneously.
Study NCT03451851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guselkumab
Description: Participants will receive a weight-based dose of guselkumab subcutaneously.
Study NCT03451851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for guselkumab
Description: Participants will receive a weight-based dose of placebo for guselkumab subcutaneously.
Study NCT03451851 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for guselkumab
Description: Participants will receive a weight-based dose of placebo for guselkumab subcutaneously.
Study NCT03451851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Participants will receive a weight-based dose of etanercept (up to 50 mg) subcutaneously.
Study NCT04118894 — intervention group
Intervention type: DEVICE
Intervention: Foot and Ankle Devices
Description: Wright devices used in foot and ankle procedures
Study NCT04645121 — intervention group
Intervention type: RADIATION
Intervention: Radioactive labelling of erythrocytes and albumin
Description: Measure blood volume, plasma volume and erythrocyte volume.
Study NCT02991664 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Equia Forte
Description: Glass ionomer restorative system
Study NCT02991664 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: G-aenial Posterior
Description: Micro hybrid composite resin
Study NCT04276727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MINT study IMP
Description: Application of gel for 6 weeks.
Study NCT04276727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MINT study IMP
Description: Application of gel for 6 weeks.
Study NCT04371302 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaire
Description: Assessment of demographics, burnout, depression and self-perceived medical errors
Study NCT04375657 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TRIIM Treatment
Description: Personalized combination of somatropin, metformin, and DHEA
Study NCT04375657 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Metformin and DHEA
Study NCT00428584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New Formulation of rebif - human interferon beta-1a
Description: New Formulation of rebif- 44 mcg, SC (sub-cutaneous) thrice weekly (tiw) injection.
Study NCT00428584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta -1b
Description: Betaseron - 250 mcg, SC (sub-cutaneous) every other day injection.
Study NCT04320758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional preparation design
Description: chamfer finish line
Study NCT04320758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biologically oriented preparation technique
Description: shoulder less preparation design
Study NCT01853618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 3.5 mg/kg or 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
Study NCT01853618 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: Performed on Day 36
Study NCT01853618 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
Study NCT01853618 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Performed on Day 36
Study NCT02593136 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Home Fortification Product (HFP)
Description: The home fortification product (HFP) is a sachet containing multiple vitamins and nutrients as follows:~Iron (Ferrous Fumarate) 12.5 mg Zinc (Zinc Gluconate) 5 mg Folic Acid 0.160 mg Vitamin-A (Vit-A Acetate) 0.30 mg Vitamin-C (Ascorbic Acid) 30 mg Vitamin-B12 0.9 mcg Iodine 90 mcg Maltodextrin (Base)
Study NCT02593136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant and Young Child Feeding (IYCF) Practices Counseling
Description: Infant and Young Child Feeding (IYCF) Practices Counseling provides direction on breast milk and milk feeding, food variety, and frequency for caregivers of children aged 6 to 18 months. Participants will be visited at least monthly by a field line worker for IYCF counseling and educational materials distribution.
Study NCT00912119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epsilon-Aminocaproic Acid
Description: Group B (intermediate dose) will receive a loading dose of EACA of 50 mg/kg over ten minutes followed by a continuous EACA infusion at 20 mg/kg/hr, which will be continued until the end of surgery
Study NCT00912119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epsilon-Aminocaproic Acid
Description: Group D (extra low dose) will receive a loading dose of EACA of 12.5 mg/kg over ten minutes followed by a continuous EACA infusion at 5 mg/kg/hr, which will be continued until the end of surgery
Study NCT00496457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Capsules of TRO19622 (125 mg)- Once a day before noon meal during 6 weeks
Study NCT04623125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spaced Retrieval Practice
Description: Online picture-naming training with 60 words which the participant experiences word-retrieval difficulties. Cards are shuffled arranged by the computerized training program.
Study NCT02104388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SJP-0035 Ophthalmic Solution
Study NCT02104388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of SJP-0035 Ophthalmic Solution
Study NCT04880902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sleeve gastrectomy
Description: Laparoscopic sleeve gastrectomy had evident therapeutic effects on preexisting obesity-related comorbidities. All patients were referred for abdominal MSCT with a volumetric assessment of gastric pouch within 1 month of surgery and 1 year postoperatively
Study NCT01917656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.8 mg administered subcutaneously (s.c., under the skin) once daily
Study NCT01917656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Subjects will continue on their pre-trial metformin tablet treatment, dose unchanged
Study NCT01917656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Subjects will continue on their pre-trial metformin tablet treatment, dose unchanged
Study NCT01917656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulphonylurea
Description: Subjects will continue on their pre-trial SU tablet treatment, doses unchanged
Study NCT03487601 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Active treatment will consist of a mild electrical current (2mA) administered via saline-soaked sponge electrodes placed along the intact scalp for 30 minutes a day for five days.
Study NCT03487601 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham transcranial direct current stimulation
Description: Sham stimulation will involve brief delivery of current in a manner that does not result in changes in neuronal firing patterns, but that is perceived as active treatment by participants.
Study NCT02560506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elastic assisted treadmill walking
Description: Rubber band pulley system that will assist therapists in advancing limbs while gait training. The device is positioned in front of a treadmill and the stretch of the elastic bands when a legs moves backwards on a treadmill is resists the movement and facilitates limb swing when walking.
Study NCT02909387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project UPLIFT
Description: UPLIFT is an 8-week distance-delivered mindfulness-based cognitive therapy intervention.
Study NCT02909387 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project UPLIFT
Description: UPLIFT is an 8-week distance-delivered mindfulness-based cognitive therapy intervention.
Study NCT00928590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost/Timolol Maleate Fixed Combination solution
Study NCT03029884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open-Loop DBS
Description: Conventional brain stimulation that is tonically providing stimulation, without feedback
Study NCT03029884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Stimulation
Description: No Active Stimulation
Study NCT03715946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection
Description: A fully human anti-programmed death 1 (PD-1) monoclonal antibody
Study NCT03715946 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Description: 45-50 Gy accelerated fractionation in 25 daily fractions, 6 fractions per week
Study NCT02149888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir/emtricitabine
Description: Once daily Tenofovir/emtricitabine (Truvada®)